Faculty
Andrea Wang-Gillam.jpg

Andrea Wang-Gillam, MD, PhD

Associate Professor
Department of Medicine
Oncology Division
Molecular Oncology & Developmental Therapeutics

Research Interests

  • Pancreatic cancer

Contact

  • 314-362-5740 (tel)
  • 314-362-7086 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Peer-reviewed Articles

  • Promising therapeutics of gastrointestinal cancers in clinical trials
    Du L, Che Z, Wang-Gillam A
    J Gastrointest Oncol 2017 Jun;8(3):524-533
  • Entering the molecular era of gastrointestinal oncology: current updates and challenges
    Wang-Gillam A, Lim KH
    J Gastrointest Oncol 2017 Jun;8(3):377-378
  • Nanoliposomal irinotecan in the clinical practice guideline for metastatic pancreatic cancer: applicability to clinical situations
    Wang-Gillam A, Von Hoff D, Siveke J, Hubner R, Belanger B, Pipas JM, Chen LT
    J Clin Oncol 2017 Feb 20;35(6):689-690
  • A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma
    Lim KH, Langley E, Gao F, Luo J, Li L, Meyer G, Kim P, Singh S, Kushnir VM, Early DS, Mullady DK, Edmundowicz SA, Wani S, Murad FM, Cao D, Azar RR, Wang-Gillam A
    Oncotarget 2017 Apr 11;8(15):24250-24261
  • Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study
    Brauer DG, Strand MS, Sanford DE, Kushnir VM, Lim KH, Mullady DK, Tan BR Jr, Wang-Gillam A, Morton AE, Ruzinova MB, Parikh PJ, Narra VR, Fowler KJ, Doyle MB, Chapman WC, Strasberg SS, Hawkins WG, Fields RC
    HPB (Oxford) 2017 Feb;19(2):133-139
  • Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis
    Pelzer U, Blanc JF, Melisi D, Cubillo A, Von Hoff DD, Wang-Gillam A, Chen LT, Siveke JT, Wan Y, Solem CT, Botteman MF, Yang Y, de Jong FA, Hubner RA
    Br J Cancer 2017 May 9;116(10):1247-1253
  • Effect of selumetinib and MK-2206 vs oxaliplatin and fluorouracil in patients with metastatic pancreatic cancer after prior therapy: SWOG S1115 study randomized clinical trial
    Chung V, McDonough S, Philip PA, Cardin D, Wang-Gillam A, Hui L, Tejani MA, Seery TE, Dy IA, Al Baghdadi T, Hendifar AE, Doyle LA, Lowy AM, Guthrie KA, Blanke CD, Hochster HS
    JAMA Oncol 2017 Apr 1;3(4):516-522
  • PET of poly (ADP-ribose) polymerase activity in cancer: preclinical assessment and first in-human studies
    Michel LS, Dyroff S, Brooks FJ, Spayd KJ, Lim S, Engle JT, Phillips S, Tan B, Wang-Gillam A, Bognar C, Chu W, Zhou D, Mach RH, Laforest R, Chen DL
    Radiology 2017 Feb;282(2):453-463
  • Constitutive IRAK4 activation underlies poor prognosis and chemoresistance in pancreatic ductal adenocarcinoma
    Zhang D, Li L, Jiang H, Knolhoff BL, Lockhart AC, Wang-Gillam A, DeNardo DG, Ruzinova MB, Lim KH
    Clin Cancer Res 2017 Apr 1;23(7):1748-1759
  • Chemotherapy-associated posterior reversible encephalopathy syndrome: a case report and review of the literature
    How J, Blattner M, Fowler S, Wang-Gillam A, Schindler SE
    Neurologist 2016 Nov;21(6):112-117
  • Racial disparities in the outcomes of patients with stage IV pancreatic adenocarcinoma are mediated by chemotherapy utilization
    Atkins JJ, Fiala MA, Wang-Gillam A, Wildes TM
    Pancreas 2016 Aug;45(7):e33-e34
  • Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy
    Jiang H, Hegde S, Knolhoff BL, Zhu Y, Herndon JM, Meyer MA, Nywening TM, Hawkins WG, Shapiro IM, Weaver DT, Pachter JA, Wang-Gillam A, DeNardo DG
    Nat Med 2016 Aug;22(8):851-60
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
    Suker M, Beumer BR, Sadot E, Marthey L, Faris JE, Mellon EA, El-Rayes BF, Wang-Gillam A, Lacy J, Hosein PJ, Moorcraft SY, Conroy T, Hohla F, Allen P, Taieb J, Hong TS, Shridhar R, Chau I, van Eijck CH, Koerkamp BG
    Lancet Oncol 2016 Jun;17(6):801-810
  • Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer
    D'Amico L, Mahajan S, Capietto AH, Yang Z, Zamani A, Ricci B, Bumpass DB, Meyer M, Su X, Wang-Gillam A, Weilbaecher K, Stewart SA, DeNardo DG, Faccio R
    J Exp Med 2016 May 2;213(5):827-840
  • Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
    Nywening TM, Wang-Gillam A, Sanford DE, Belt BA, Panni RZ, Cusworth BM, Toriola AT, Nieman RK, Worley LA, Yano M, Fowler KJ, Lockhart AC, Suresh R, Tan BR, Lim KH, Fields RC, Strasberg SM, Hawkins WG, DeNardo DG, Goedegebuure SP, Linehan DC
    Lancet Oncol 2016 May;17(5):651-662
  • Long-term ERK inhibition in KRAS-mutant pancreatic cancer is associated with MYC degradation and senescence-like growth suppression
    Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ
    Cancer Cell 2016 Jan 11;29(1):75-89
  • Induction chemotherapy followed by concurrent full-dose gemcitabine and intensity-modulated radiation therapy for borderline resectable and locally advanced pancreatic adenocarcinoma
    Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ
    Am J Clin Oncol 2016 Feb;39(1):1-7
  • A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors
    Amin M, Minton SE, LoRusso PM, Krishnamurthi SS, Pickett CA, Lunceford J, Hille D, Mauro D, Stein MN, Wang-Gillam A, Trull L, Lockhart AC
    Invest New Drugs 2016 Feb;34(1):84-95
  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
    Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT
    NAPOLI-1 Study Group

    Lancet 2016 Feb 6;387(10018):545-57
  • Immunogenicity of influenza vaccination in patients with cancer
    Waqar SN, Boehmer L, Morgensztern D, Wang-Gillam A, Sorscher S, Lawrence S, Gao F, Guebert K, Williams K, Govindan R
    Am J Clin Oncol 2015 Dec 14; [Epub ahead of print]
  • Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study
    Pedersen KS, Kim GP, Foster NR, Wang-Gillam A, Erlichman C, McWilliams RR
    Invest New Drugs 2015 Aug;33(4):963-968
  • A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma
    Cho M, Wang-Gillam A, Myerson R, Gao F, Strasberg S, Picus J, Sorscher S, Fournier C, Nagaraj G, Parikh P, Suresh R, Linehan D, Tan BR
    HPB (Oxford) 2015 Jul;17(7):587-93
  • Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer
    Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM
    J Clin Oncol 2015 Apr 20;33(12):1325-33
  • Comparison of implanted fiducial markers and self-expandable metallic stents for pancreatic image guided radiation therapy localization
    Pepin E, Olsen L, Badiyan S, Murad F, Mullady D, Wang-Gillam A, Linehan D, Parikh P, Olsen J
    Pract Radiat Oncol 2015 May-Jun;5(3):e193-9
  • Natural history of preoperative subcentimeter pulmonary nodules in patients with resectable pancreatic adenocarcinoma: a retrospective cohort study
    Chang ST, Nguyen DC, Raptis C, Menias CO, Zhou G, Wang-Gillam A, Linehan DC, Hawkins WG, Strasberg SM, Fields RC
    Ann Surg 2015 May;261(5):970-5
  • Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers
    Goff LW, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauer B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC
    PLoS One 2014 Sep 18;9(9):e107424
  • Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors
    Lockhart AC, Sundaram S, Sarantopoulos J, Mita MM, Wang-Gillam A, Moseley JL, Barber SL, Lane AR, Wack C, Kassalow L, Dedieu JF, Mita AC
    Invest New Drugs 2014 Dec;32(6):1236-45
  • CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models
    Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG
    Cancer Res 2014 Sep 15;74(18):5057-69
  • A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
    Wang-Gillam A, Thakkar N, Lockhart AC, Williams K, Baggstrom M, Naughton M, Suresh R, Ma C, Tan B, Lee W, Jiang X, Mwandoro T, Trull L, Belanger S, Creekmore AN, Gao F, Fracasso PM, Picus J
    Cancer Chemother Pharmacol 2014 Aug;74(2):419-26
  • Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer
    Panni RZ, Sanford DE, Belt BA, Mitchem JB, Worley LA, Goetz BD, Mukherjee P, Wang-Gillam A, Link DC, DeNardo DG, Goedegebuure SP, Linehan DC
    Cancer Immunol Immunother 2014 May;63(5):513-28
  • Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer
    Myerson RJ, Tan B, Hunt S, Olsen J, Birnbaum E, Fleshman J, Gao F, Hall L, Kodner I, Lockhart AC, Mutch M, Naughton M, Picus J, Rigden C, Safar B, Sorscher S, Suresh R, Wang-Gillam A, Parikh P
    Int J Radiat Oncol Biol Phys 2014 Mar 15;88(4):829-36
  • Supportive care considerations during concurrent chemoradiotherapy for pancreatic adenocarcinoma: lessons learned from clinical experience
    Wang-Gillam A, Abrams RA, Posner MC, Pisters PW, Picozzi VJ
    Am J Clin Oncol 2013 Dec;36(6):637-43
  • Changing the way we do business: recommendations to accelerate biomarker development in pancreatic cancer
    Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchant N, Moore M, Pleskow D, Wang-Gillam A, Lowy AM
    Clin Cancer Res 2013 Feb 1;19(3):538-540
  • Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma
    Cho M, Peddi PF, Ding K, Chen L, Thomas D, Wang J, Lockhart AC, Tan B, Wang-Gillam A
    J Transl Med 2013 Sep 8;11:206
  • Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models
    Zhong H, Sanchez C, Spitrzer D, Plambeck-Suess S, Gibbs J, Hawkins WG, Denardo D, Gao F, Pufahl RA, Lockhart AC, Xu M, Linehan D, Weber J, Wang-Gillam A
    PLoS One 2013 Oct 9;8(10):e77243
  • A study of zoledronic acid as neo-adjuvant, perioperative therapy in patients with resectable pancreatic ductal adenocarcinoma
    Sanford DE, Porembka MR, Panni RZ, Mitchem JB, Belt BA, Plambeck-Suess SM, Lin G, Denardo DG, Fields RC, Hawkins WG, Strasberg SM, Lockhart AC, Wang-Gillam A, Goedegebuure SP, Linehan DC
    J Cancer Ther 2013 May;4(3):797-803
  • Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma
    Peddi PF, Cho M, Wang J, Gao F, Wang-Gillam A
    J Gastrointest Oncol 2013 Dec;4(4):370-3
  • Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis
    Sanford DE, Belt BA, Panni RZ, Mayer A, Deshpande AD, Carpenter D, Mitchem JB, Plambeck-Suess SM, Worley LA, Goetz BD, Wang-Gillam A, Eberlein TJ, Denardo DG, Goedegebuure SP, Linehan DC
    Clin Cancer Res 2013 Jul 1;19(13):3404-15
  • Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses
    Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG
    Cancer Res 2013 Feb 1;73(3):1128-1141
  • A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
    Wang-Gillam A, Plambeck-Suess S, Goedegebuure P, Simon PO, Mitchem JB, Hornick JR, Sorscher S, Picus J, Suresh R, Lockhart AC, Tan B, Hawkins WG
    Invest New Drugs 2013 Jun;31(3):707-13
  • Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma
    Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, Suresh R, Lockhart AC, Wang J, Menias C, Gao F, Linehan D, Wang-Gillam A
    JOP 2012 Sep 10;13(5):497-501
  • A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors
    Wang-Gillam A, Arnold SM, Bukowski RM, Rothenberg ML, Cooper W, Wang KK, Gauthier E, Lockhart AC
    Invest New Drugs 2012 Feb;30(1):266-72
  • A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
    Wang-Gillam A, Tew WP, Rothenberg ML, Dupont J, Cooper W, Sternas L, Buzenet G, Sosman JA, Spriggs DR, Lockhart AC
    Invest New Drugs 2012 Oct;30(5):1958-61
  • Influence of obesity and other risk factors on survival outcomes in patients undergoing pancreaticoduodenectomy for pancreatic cancer
    Dandona M, Linehan D, Hawkins W, Strasberg S, Gao F, Wang-Gillam A
    Pancreas 2011 Aug;40(6):931-7
  • A survey of Internet utilization among patients with cancer
    Castleton K, Fong T, Wang-Gillam A, Waqar MA, Jeffe DB, Kehlenbrink L, Gao F, Govindan R
    Support Care Cancer 2011 Aug;19(8):1183-90
  • Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic
    Wang-Gillam A, Williams K, Novello S, Gao F, Scagliotti GV, Govindan R
    J Clin Oncol 2010 Aug 20;28(24):3803-7
  • Re: ABO blood group and the risk of pancreatic cancer
    Dandona M, Gao F, Linehan DC, Wang-Gillam A
    J Natl Cancer Inst 2010 Jan 20;102(2):135-7
  • Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates
    Wang-Gillam A, Miles DA, Hutchins LF
    Oncologist 2008 Jul;13(7):821-7
  • Experiences of institutional review board (IRB) and protocol review and monitoring committee (PRMC) rotations in hematology/oncology training
    Wang-Gillam A, Valentine J, Sherman AC, Mehta P
    J Cancer Educ 2008 Summer;23(2):71-3
  • Anti-tumor effect of doxycycline on glioblastoma cells
    Wang-Gillam A, Siegle E, Mayes D, Hutchins L, Zhou YH
    J Cancer Mol 2007;3(5):147-153
  • Acute splenic sequestration crisis resembling sepsis in an adult with hemoglobin SC disease
    Wang-Gillam A, Lee RS, Hsi ED, Brotman DJ
    South Med J 2004 Apr;97(4):413-5
  • Identification and modification of the uridine-binding site of the UDP-GalNAc (GlcNAc) pyrophosphorylase
    Wang-Gillam A, Pastuszak I, Stewart M, Drake RR, Elbein AD
    J Biol Chem 2000 Jan 14;275(2):1433-8
  • A 17-amino acid insert changes UDP-N-acetylhexosamine pyrophosphorylase specificity from UDP-GalNAc to UDP-GlcNAc
    Wang-Gillam A, Pastuszak I, Elbein AD
    J Biol Chem 1998 Oct 16;273(42):27055-7